
Hosted by Tom Hickey · EN

What if frontline clinicians everywhere had instant access to expert-level stroke imaging — no matter where a patient arrives? In this episode of Med Tech Gurus, we're joined by Michalis Papadakis, CEO and Co-Founder of Brainomix, an Oxford University spin-out using AI to transform how stroke is diagnosed and treated. With a background in neuroscience from Imperial College London, UCL, and the University of Oxford, Michalis built Brainomix with a singular mission: ensure patients don't miss out on life-saving stroke treatments due to delays or lack of imaging expertise. Under his leadership, Brainomix developed Brainomix 360 Stroke, the world's first fully automated AI imaging suite for stroke care — now deployed in more than 30 countries, backed by 50+ clinical publications, and processing patient scans in minutes with results delivered in under sixty seconds. In this conversation, we explore how starting with a true clinical unmet need, relentless evidence generation, and seamless workflow integration enabled Brainomix to scale globally and materially improve patient outcomes. If you care about AI in healthcare, stroke innovation, clinical adoption, or scaling medtech from academia to enterprise, this is a blueprint worth hearing.

Why do so many great MedTech products stall after launch — even when the data is there? In this episode of Med Tech Gurus, we're joined by Amy Brouhle, Vice President of Strategic Business Development at S2N Health. A former emergency department nurse turned commercialization leader, Amy brings more than 20 years of experience spanning clinical care, GPO strategy, national accounts, and MedTech growth. Her career includes senior roles at Vizient, Hillrom, and GE Healthcare, giving her a rare, end-to-end view of how innovation actually gets adopted — or stuck. At S2N Health, Amy helps MedTech companies cut through the noise of fragmented data and turn insight into action. We explore why most organizations don't have a data problem — they have an insight problem — and how aligning sales, marketing, and strategy around the right signals can unlock utilization, accelerate adoption, and improve investor confidence. From GPO dynamics and channel strategy to AI-powered targeting, territory planning, and go-to-market execution, Amy shares practical lessons every founder and commercial leader needs to hear. If you're trying to translate innovation into revenue and scale, this is a conversation you won't want to miss.

Why has healthcare resisted digital transformation longer than almost any other industry? In this episode of Med Tech Gurus, we're joined by Mariano García-Valiño, four-time entrepreneur, digital health innovator, and CEO of AXENYA—recently named one of the world's best digital health companies by Newsweek. Mariano has built, scaled, and exited billion-dollar healthcare companies by combining technology, data, and human-centered design to tackle chronic disease at scale. Mariano is also the author of Inedible, where he argues that modern healthcare is still built for acute illness, not the chronic conditions driving today's costs and outcomes. In this conversation, we explore why software alone isn't enough, how AI and continuous care models unlock real impact, and what it actually takes to scale health tech in complex, regulated markets. From leadership and entrepreneurship to AI-enabled care delivery, Mariano shares hard-earned lessons on building companies with both scale and purpose. If you care about digital health, healthcare transformation, or meaningful innovation, this is a conversation you won't want to miss.

What if the most dangerous part of brain tumor treatment isn't the surgery… but the wait that comes after it? In this episode of Med Tech Gurus, we sit down with Dr. Michael Garcia, Chief Medical Officer and Head of Clinical Development at GT Medical Technologies, and one of the leading voices reshaping how we treat brain tumors. Dr. Garcia leads the clinical strategy behind GammaTile® — an implantable, bioabsorbable device that delivers targeted radiation from inside the brain immediately after surgery, eliminating the dangerous 3–6 week delay where tumors often begin to grow back. Under his leadership, GT Medical has reported powerful interim clinical data showing GammaTile can reduce the risk of recurrence or death by more than 50% compared to standard of care — with no increase in safety concerns. Today, more than 150 leading cancer centers are using this technology, changing not only outcomes, but something equally important: patient experience. Less anxiety. Fewer treatment delays. Fewer logistical burdens. More hope. Dr. Garcia shares the science, the strategy, and the deeply personal mission behind this innovation — along with insights on clinical trial design, multidisciplinary collaboration, and building medtech that truly serves patients. If you care about oncology, neurosurgery, innovation with purpose, or patient-centered design, this is a conversation you won't want to miss.

What happens when rocket-science precision meets frontline healthcare? In this episode of Med Tech Gurus, we sit down with Professor Mark Kendall, Founder & CEO of WearOptimo and one of the world's most visionary biomedical innovators. A former rocket scientist turned medtech pioneer, Mark has already transformed vaccine delivery with groundbreaking platforms like PowderJet and Vaxxas. Now, he's doing it again — this time with a revolutionary micro-wearable sensor designed to pull high-fidelity biosignals directly from the skin without painful needles or invasive hardware. Mark explains how WearOptimo's sticker-like microneedle patch, built using cutting-edge manufacturing techniques that scale to tens of millions of units, is redefining what wearables can do. The first target? Hydration monitoring — solving a problem so widespread it quietly reduces life expectancy and affects elite athletes, surgical outcomes, and everyday health. From scalable manufacturing and AI-enabled biomarker intelligence, to building elite teams and navigating fundraising, Mark delivers powerful lessons on innovation, leadership, and building technologies that truly matter. If you're passionate about the future of wearable medicine, platform technology, and designing solutions that actually reach the real world, this conversation is one you won't want to miss.

What if getting breakthrough devices to the right patients wasn't a guessing game — but a data-driven science? In this episode of Med Tech Gurus, we sit down with Mike Monovoukas, CEO and Co-Founder of AcuityMD, one of the fastest-growing platforms in MedTech. Mike shares how his team is turning mountains of messy healthcare data into clear, actionable insights — helping innovators pinpoint the right physicians, facilities, and patient populations, and transforming how devices reach the people who need them most. We explore how AcuityMD is powering precision targeting through AI, why democratizing market intelligence helps level the playing field for new entrants, and how smarter commercialization can unlock access for underserved communities — including their work helping EPI bring the Alpha-Stim device to veterans struggling with pain, insomnia, and anxiety. From designing platforms built specifically for MedTech, to making complex data simple for frontline sales teams, to reshaping how companies scale, Mike delivers a masterclass in building for the future of commercialization — where evidence, empathy, and AI come together.

What if the Make America Healthy Again (MAHA) movement isn't political noise—but a powerful signal that patient expectations are fundamentally changing? In this episode of Med Tech Gurus, we sit down with Noël Theodosiou, CEO of Luminous, to explore the growing trust gap between life sciences companies and the patients they serve. Noël challenges leaders to move beyond a traditional "we know best" mindset and embrace a biopsychosocial, patient-centered approach to innovation. From GLP-1 adoption trends to AI-driven health searches, we discuss why co-creation, prevention, and clearer separation between science and promotion are critical to rebuilding credibility. For founders, executives, and investors navigating today's shifting healthcare landscape, this conversation delivers practical insight into aligning innovation with modern patient expectations.

In this episode of Med Tech Gurus, we sit down with Dr. Adam S. Arthur, Chief Medical Officer for Medtronic's Neurovascular business — and one of the most influential voices in modern stroke care. With more than 20 years as a practicing neurosurgeon, clinical researcher, and academic leader, Dr. Arthur has helped redefine standards of care for ischemic stroke, hemorrhagic stroke, carotid disease, and neurovascular innovation worldwide. Now at Medtronic, he's leading the charge to translate real-world clinical insight into breakthrough devices that scale — from next-generation thrombectomy tools to new applications for established technologies like Onyx, and a pipeline of neurostimulation, robotics, and endovascular therapies that promise to change what's possible for brain health. Dr. Arthur shares powerful lessons from decades of clinical trials, including why "the devil is in the details," how honest collaboration between physicians and industry accelerates innovation, and why failing fast is often the quickest path to breakthroughs. He also offers an exciting look at the future: remote robotics, closed-loop vagus nerve stimulation, and new ways to reach stroke patients with life-saving precision. If you care about the future of stroke care, neurovascular devices, or scaling innovation responsibly, this episode delivers a masterclass from one of the field's true thought leaders.

In this episode of Med Tech Gurus, we're joined by John Dugas and Dr. Kevin Schwarz of Solventum Medical—two leaders pushing wearable innovation into its next era. With expertise spanning chemical engineering, materials science, synthetic biology, and global R&D, John and Kevin show how truly breakthrough wearables demand far more than clever sensors. They require world-class adhesives, smart overlays, skin-friendly materials, and device designs that survive real life—not just the lab. They explain why longer wear time is becoming one of the biggest drivers of clinical success, how thin-film overlays can quadruple device survivability, and why understanding patient behavior is just as important as engineering excellence. From global scale to skin biomechanics, this episode delivers a powerful look at what it really takes to build wearables that stay on, stay comfortable, and stay effective. If you're building the next generation of chronic disease tools, diagnostics, or connected care devices — this conversation is packed with insights you won't want to miss.

In this episode of Med Tech Gurus, we welcome Neil Klompas, Chief Executive Officer of Augurex Life Sciences. With more than two decades of experience leading companies at the intersection of diagnostics, rheumatology, and translational medicine, Neil is pioneering a new era of autoimmune biomarker discovery. Under his leadership, Augurex developed SpineStat, the world's first blood test designed to identify axial spondyloarthritis (AxSpA)—a chronic inflammatory spinal disease that affects millions yet often goes undiagnosed for nearly a decade. By leveraging the anti-14-3-3η autoantibody in combination with CRP, SpineStat is helping clinicians detect disease earlier, prevent irreversible spinal damage, and even reduce opioid dependence through faster, targeted treatment. Neil shares how engaging early with regulators helped Augurex earn FDA Breakthrough Device Designation, why he believes rheumatology is poised for its "oncology moment," and how keeping his team centered on the patient journey drives innovation every day. If you're passionate about precision diagnostics, regulatory navigation, and building mission-driven teams, this episode is a masterclass in turning unmet medical need into measurable clinical impact.